



Announcement Summary

Entity name
TELEX PHARMACEUTICALS LIMITED

Announcement Type
New announcement

Date of this announcement
Monday March 17, 2025

The +securities to be quoted are:
Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

Issue of Telix ordinary shares to Dedicaid GmbH sellers following satisfaction of an agreed contractual milestone related to regulatory approval of the purchased clinical decision support software AI platform. Refer ASX release dated 27 April 2023.

Total number of +securities to be quoted

ASX +security code	Security description	Number of +securities to be quoted	Issue date
TLX	ORDINARY FULLY PAID	13,356	17/03/2025

Refer to next page for full details of the announcement



Part 1 - Entity and announcement details

1.1 Name of entity

TELIX PHARMACEUTICALS LIMITED

We (the entity named above) apply for +quotation of the following +securities and agree to the matters set out in Appendix 2A of the ASX Listing Rules.

1.2 Registered number type

ACN

Registration number

616620369

1.3 ASX issuer code

TLX

1.4 The announcement is

New announcement

1.5 Date of this announcement

17/3/2025



Part 2 - Type of Issue

2.1 The +securities to be quoted are:

Other

Please refer to the response to Q2.3d for further information about the type of securities to be quoted and the circumstances of the issue.

2.2 The +class of +securities to be quoted is:

Additional +securities in a class that is already quoted on ASX ("existing class")

2.3c Have these +securities been offered under a +disclosure document or +PDS?

No

2.3d Please provide any further information needed to understand the circumstances in which you are applying to have these +securities quoted on ASX, including why the issue of the +securities has not been previously announced to the market in an Appendix 3B

Issue of Telix ordinary shares to Dedicaid GmbH sellers following satisfaction of an agreed contractual milestone related to regulatory approval of the purchased clinical decision support software AI platform. Refer ASX release dated 27 April 2023.

2.4 Any on-sale of the +securities to be quoted within 12 months of their date of issue will comply with the secondary sale provisions in sections 707(3) and 1012C(6) of the Corporations Act by virtue of:

The publication of a cleansing notice under section 708A(5), 708AA(2)(f), 1012DA(5) or 1012DAA(2)(f)



Part 3B - number and type of +securities to be quoted (existing class) where issue has not previously been notified to ASX in an Appendix 3B

Additional +securities to be quoted in an existing class

ASX +security code and description

TLX : ORDINARY FULLY PAID

Issue date

17/3/2025

Will the +securities to be quoted rank equally in all respects from their issue date with the existing issued +securities in that class?

Yes

Issue details

Number of +securities to be quoted

13,356

Are the +securities being issued for a cash consideration?

No

Please describe the consideration being provided for the +securities

Telix issued 13,356 ordinary shares equivalent to 220,000 Euros calculated in accordance with agreed formula noted below on satisfaction of a contractual milestone event. Refer ASX release 27/04/23.

Please provide an estimate (in AUD) of the value of the consideration being provided per +security for the +securities to be quoted

28.490500

Any other information the entity wishes to provide about the +securities to be quoted

Telix issued 13,356 ordinary shares equivalent to 220,000 Euros on satisfaction of a contractual milestone event calculated by converting WVAP of Telix shares for 10 trading days up to and including 11 March 2025 of \$28.4905 to Euros using the RBA exchange rate on 11 March 2025 (AUD:Euros 0.5782) for a Euro WVAP of 16,4732 euros, and then dividing the 220,000 Euros by the Euro WVAP calculated. 72.5% of ordinary shares issued (9,684) will be subject to voluntary escrow for 30 days from issue.

The purpose(s) for which the entity is issuing the securities

To pay for the acquisition of an asset

Please provide additional details

Partial earn-out payment of total 1.1 million Euros agreed to be paid to the Dedicaid sellers on satisfaction of agreed milestone events. Refer ASX release dated 27 April 2023.



Part 4 - Issued capital following quotation

Following the quotation of the +securities the subject of this application, the issued capital of the entity will comprise:

The figures in parts 4.1 and 4.2 below are automatically generated and may not reflect the entity's current issued capital if other Appendix 2A, Appendix 3G or Appendix 3H forms are currently with ASX for processing.

4.1 Quoted +securities (total number of each +class of +securities quoted on ASX following the +quotation of the +securities subject of this application)

ASX +security code and description	Total number of +securities on issue
TLX : ORDINARY FULLY PAID	336,885,664

4.2 Unquoted +securities (total number of each +class of +securities issued but not quoted on ASX)

ASX +security code and description	Total number of +securities on issue
TLXAQ : SHARE RIGHTS EXPIRING 13-JUN-2027 EX NIL	80,000
TLXAR : PERFORMANCE RIGHTS	10,469,979
TLXAP : SHARE RIGHTS	1,665,000
TLXAO : SHARE APPRECIATION RIGHTS	15,400,822
TLXAT : CONVERTIBLE NOTES	3,250
TLXAM : OPTION EXPIRING 20-JUL-2026 EX \$5.37	404,992
TLXAN : SHARE RIGHTS EXPIRING 20-JUL-2026 EX NIL	100,000
TLXAL : OPTION EXPIRING 27-JAN-2026 EX \$4.38	349,361
TLXAS : PERFORMANCE SHARE INCENTIVE RIGHTS	440,000



Part 5 - Other Listing Rule requirements

5.1 Are the +securities being issued under an exception in Listing Rule 7.2 and therefore the issue does not need any security holder approval under Listing Rule 7.1?

No

5.2 Has the entity obtained, or is it obtaining, +security holder approval for the issue under listing rule 7.1?

No

5.2b Are any of the +securities being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

Yes

5.2b.1 How many +securities are being issued without +security holder approval using the entity's 15% placement capacity under listing rule 7.1?

13,356

5.2c Are any of the +securities being issued without +security holder approval using the entity's additional 10% placement capacity under listing rule 7.1A (if applicable)?

N/A